Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c